What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?
Within a year, the investing legend has doubled down on his latest pharma bet
Himanshu Kakkar - May 23, 2020
Cipla’s American Odyssey
The pharma major has made a few tough decisions over the past few years. Now, it’s beginning to pay off
Kripa Mahalingam - January 22, 2020
Seeking a Safe Haven
As the market tumbles, mutual fund managers recommend pharma, private banks and specialty chemicals to tide over the volatility
Prathamesh Mulye - January 08, 2019
Uphill Climb
The pharma industry has to deal with poor road connectivity and an unskilled labour force in Sikkim, but it seems to have made peace with the mountains
Himanshu Kakkar - January 25, 2019
Inflection point
Laurus Labs is crucially poised, as investors look forward to its R&D efforts finally paying off
Khushboo Balani - April 04, 2018
Opportunistic Buyer
Sailesh Raj Bhan has made optimum use of cyclical downturns to deliver outperformance
Khushboo Balani - January 25, 2018
Nursing Back to Health
A strong product pipeline and receding US FDA threat could well turn the tide in favour of the beleaguered pharma players
Jash Kriplani - October 18, 2017
Ajay Relan
His bet on Natco Pharma’s differentiated product portfolio paid off while Monnet Ispat taught him to be wary of over-ambitious entrepreneurs
Krishna Gopalan - September 18, 2017
Kick The Butt
To quit smoking isn't easy but it's possible, Nicotex shows you how
Somdyuti Datta Ray - September 20, 2017
Under The Weather - Part 2
Even as it battles the US FDA, the industry has been caught off-guard by policy changes back home
Krishna Gopalan - June 05, 2017
